Momenta Pharmaceuticals, Inc. (MNTA) Financial Statements (2024 and earlier)

Company Profile

Business Address 301 BINNEY STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:487,872545,110325,862344,074416,453449,411
Cash and cash equivalents179,690382,515122,131123,508131,228248,334
Short-term investments283,544139,129149,599146,866204,043174,076
Other undisclosed cash, cash equivalents, and short-term investments24,63823,46654,13273,70081,18227,001
Restricted cash and investments    36,049  
Receivables  8,013   11,371
Asset, held-for-sale, not part of disposal group   125180710 
Other current assets    6,094  
Other undisclosed current assets2,481(13,996)(39,843)(69,302)(70,880)(19,359)
Total current assets:490,353539,127286,144317,095346,283441,423
Noncurrent Assets
Property, plant and equipment11,24711,49911,55511,83715,13020,944
Long-term investments and receivables24,63823,46654,13273,70081,18227,001
Long-term investments24,63823,46654,13273,70081,18227,001
Intangible assets, net (including goodwill)1,4411,7302,0182,3062,5952,883
Intangible assets, net (excluding goodwill)1,4411,7302,0182,3062,5952,883
Restricted cash and investments  1,8491,8491,84937,89837,898
Other noncurrent assets39,21840,69442,07072,89975,3621,414
Other undisclosed noncurrent assets1,849     
Total noncurrent assets:78,39379,238111,624162,591212,16790,140
TOTAL ASSETS:568,746618,365397,768479,686558,450531,563
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities52,45872,93929,67125,41819,69523,412
Accounts payable2,45014,1403,45910,3999,3199,352
Accrued liabilities50,00858,79926,21215,01910,37614,060
Deferred revenue7488959391,731 
Restructuring reserve34342571,1111,5563,235
Contract with customer, liability3,6063,916
Other liabilities27,95228,1135,4319,22323,95316,227
Other undisclosed current liabilities1,9664,1234,2834,2722,7704,721
Total current liabilities:83,158106,10440,58141,75551,58051,511
Noncurrent Liabilities
Liabilities, other than long-term debt57,39557,80181,263125,21284,31219,044
Deferred revenue8959401,1831,112 
Contract with customer, liability7431,774
Other liabilities56,50056,86180,080124,10083,56917,270
Total noncurrent liabilities:57,39557,80181,263125,21284,31219,044
Total liabilities:140,553163,905121,844166,967135,89270,555
Equity
Equity, attributable to parent428,193454,460275,924312,719422,558461,008
Common stock121210101010
Treasury stock, value(3,114)(3,114)(3,114)(3,114)(3,114)(3,114)
Additional paid in capital1,504,8501,491,1471,225,7481,217,9421,214,0761,208,025
Accumulated other comprehensive income (loss)(119)296461519255(87)
Accumulated deficit(1,073,436)(1,033,881)(947,181)(902,638)(788,669)(743,826)
Total equity:428,193454,460275,924312,719422,558461,008
TOTAL LIABILITIES AND EQUITY:568,746618,365397,768479,686558,450531,563

Income Statement (P&L) ($ in thousands)

6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
Revenues8,8898,1826,3915,1824,11342,822
Gross profit:8,8898,1826,3915,1824,11342,822
Operating expenses(49,557)(95,462)(52,485)(121,808)(52,204)(52,492)
Operating loss:(40,668)(87,280)(46,094)(116,626)(48,091)(9,670)
Nonoperating income1,1135801,5512,6573,2481,425
Other undisclosed loss from continuing operations before equity method investments, income taxes  (2,018)    
Loss from continuing operations:(39,555)(88,718)(44,543)(113,969)(44,843)(8,245)
Loss before gain (loss) on sale of properties:(39,555)(88,718)(44,543)(113,969)(44,843)(8,245)
Net loss attributable to parent:(39,555)(88,718)(44,543)(113,969)(44,843)(8,245)
Other undisclosed net income available to common stockholders, basic  2,018    
Net loss available to common stockholders, diluted:(39,555)(86,700)(44,543)(113,969)(44,843)(8,245)

Comprehensive Income ($ in thousands)

6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
Net loss:(39,555)(88,718)(44,543)(113,969)(44,843)(8,245)
Comprehensive loss:(39,555)(88,718)(44,543)(113,969)(44,843)(8,245)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(415)1,853(58)26434277
Comprehensive loss, net of tax, attributable to parent:(39,970)(86,865)(44,601)(113,705)(44,501)(8,168)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: